Clinical Trial Update: Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing nebivolol, losartan, and nebivolol plus losartan for preventing aortic root dilation in genotyped Marfan syndrome patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marfan Syndrome

Drugs mentioned

• Losartan (losartan)
• Nebivolol (Nebivolol)
• Nebivolol+Losartan

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Marfan Syndrome | Phase 3 | Status: UNKNOWN